BioElectronics Corporation Announces the Publication of a Canine Arthritis Study
96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement
FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408